This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Stock Moves -1.36%: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $9.43, marking a -1.36% move from the previous day.
Teladoc Health Q4 Loss Widens on Soft Integrated Care Unit
by Zacks Equity Research
TDOC expects revenues in the Integrated Care segment to witness 0-3% growth on a year-over-year basis.
Here's What Key Metrics Tell Us About Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of -33.33% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of Teladoc (TDOC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Teladoc (TDOC) Surges 8.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $10.05, denoting a -1.08% change from the preceding trading day.
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Surgery Partners (SGRY) Surges 21.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $10.21, moving +1.19% from the previous trading session.
Teladoc (TDOC) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $9.09, denoting a -0.76% change from the preceding trading day.
Teladoc Partners With Amazon to Expand Chronic Care Program Reach
by Zacks Equity Research
TDOC collaborates with Amazon to enhance its reach for chronic condition management programs.
Teladoc (TDOC) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $9.52, making no change from the previous trading session.
Should Value Investors Buy Teladoc Health (TDOC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teladoc (TDOC) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $9.45, signifying a -0.84% move from its prior day's close.
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
by Indrajit Bandyopadhyay
Hims & Hers Health sees robust 2024 growth with $401.6-million Q3 revenues (+77% YoY), 2M+ subscribers and plans to exceed $1.5B in revenues in 2024. Where will the stock go?
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
by Zacks Equity Research
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Up 27% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc Stock Rises 59.4% in Three Months: Is This Your Buy Signal?
by Zacks Equity Research
TDOC's use of machine learning and AI continues to drive healthcare innovation.
Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery
by Zacks Equity Research
TDOC's upgraded Virtual Sitter uses AI to prevent patient falls, boost staff efficiency and enhance care delivery, thus addressing major challenges in hospitals and health systems.
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Teladoc Health Q3 Loss Narrows on Strong Integrated Care Unit
by Zacks Equity Research
TDOC expects 2024 U.S. Integrated Care Members to remain within 93.5-94.5 million.
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.